Kidney Drug's hidden heart benefits under the microscope
NCT ID NCT05719714
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study looks at how dapagliflozin, a diabetes drug, affects heart function and metabolism in people with chronic kidney disease. Researchers will measure heart strain, oxygen use during exercise, and blood chemicals in 60 adults. The goal is to understand how the drug works beyond its usual effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University
Chicago, Illinois, 60607, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can a new graft keep dialysis access working longer?